LRPPRC and prostate cancer: Of these, 10 sites (LRPPRC, CLDN11, MTOR, EPB41, DAPK1, PPZR2B, ZDHHC2, HSD17B13, MYOM2 and MAN1A1) were linked to decreased expression and increased aggressiveness/p-EMT, which may be of clinical importance for identifying an aggressive p-EMT phenotype in prostate cancer patients in the future (Figure 6C, Table 1).